Biomea Fusion (BMEA) announced that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock and accompanying warrants to purchase shares of its common stock. All of the shares, pre-funded warrants and accompanying common stock warrants to be sold in the proposed offering are to be sold by Biomea. Jefferies is acting as sole book running manager for the proposed offering.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMEA:
- Biomea Fusion reports inducment grants under Nasdaq listing rule
- Biomea Fusion: Promising Clinical Pipeline and Strategic Focus Drive Buy Rating
- Biomea Fusion announces presentation of preclinical data on icovamenib
- Five Below upgraded, Bill downgraded: Wall Street’s top analyst calls
- Biomea Fusion initiated with a Buy at Jefferies
